



Insulet to Showcase its Recently-Launched Omnipod® DASH™ System and Present Seven Scientific Abstracts at the American Diabetes Association's 79th Scientific Sessions

June 6, 2019

No-Cost Personal Diabetes Manager, No Four Year Lock-in Period, and New User Interface Allow for Smooth Transition from Multiple Daily Injections (MDI) to Pod Therapy

ACTON, Mass.--(BUSINESS WIRE)--Jun. 6, 2019-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in [tubeless insulin pump](#) technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its new Omnipod DASH™ Insulin Management System (Omnipod DASH System), during the [American Diabetes Association](#) (ADA) 79th Scientific Sessions at the Moscone Center in San Francisco, California, June 7-11, 2019. Insulet will also have a robust clinical presence at the meeting with seven accepted abstracts, including six posters and one oral presentation.

Insulet will feature its new, innovative Omnipod DASH System in a product theater, a variety of hands-on, interactive product demonstrations, and other events during the show and at its exhibit booth (#1823). The Omnipod DASH System allows individuals to discreetly manage their diabetes with just a few finger taps while enjoying the freedom from daily injections, tubing hassles and wardrobe compromises. The Omnipod DASH System is intended to streamline workflow for prescribers and make diabetes a smaller part of life for people with diabetes and their caregivers.

The Company will also present new research results for its innovation pipeline, including Insulet's Omnipod Horizon™ Automated Insulin Delivery System evidencing its safety and performance in young children aged two- to six- years with type 1 diabetes, as well as additional real-world data on long-term clinical outcomes from over 20,000 Omnipod System users, which further support the benefits of the Omnipod System.

"We are thrilled to be in full market release with our new Omnipod DASH System, which is designed to be the best and easiest-to-use insulin delivery system available," said Bret Christensen, Executive Vice President and Chief Commercial Officer. "We know our customers are counting on us to deliver the highest quality products and support, which is why we are pleased to present compelling new research demonstrating the significant and continued progress we are making on our innovation pathway."

For more about Insulet's future innovation pipeline, please visit myomnipod.com/innovation.

A schedule of Insulet clinical presentations at ADA is as follows:

Time	Presentation	Location
Saturday, June 8		
11:30 AM – 12:30 PM	1453-P Glycemic Profiles and Insulin Use in 2,313 Medicare-Eligible Older Adults with Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management	Poster Hall
	Jennifer E. Layne, Jialun He, Jay Jantz, Yibin Zheng, Eric Benjamin, Trang T. Ly	
Sunday, June 9		
12:00 – 1:00 PM	1042-P Real-World Treatment Patterns and Glycemic Profiles of 1,217 Adults with Type 2 Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management	Poster Hall
	Jennifer E. Layne, Jay Jantz, Jialun He, Yibin Zheng, Eric Benjamin, Trang T. Ly	
12:00 – 1:00 PM	1043-P Glycemic Profiles and Treatment Patterns: Real-World Data from 8,020 Adults with Type 1 Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management	Poster Hall
	Jennifer E. Layne, Jialun He, Jay Jantz, Yibin Zheng, Eric Benjamin, Trang T. Ly	
12:00 – 1:00 PM	1055-P Glucose Management Indicator Results from Real-World Data of 1,838 Patients with Type 1 Diabetes Using the Omnipod® Insulin Management System with Continuous Glucose Monitoring and Cloud-Based Data Management	Poster Hall

Jennifer E. Layne, Jay Jantz, Yibin Zheng, Jialun He, Eric Benjamin, Trang T. Ly

1061-P Effect of the Omnipod® Insulin Management System on Glycemic Control in Adults with Type 1 Diabetes Previously Treated with MDI or CSII

12:00 – 1:00
PM

Poster Hall

Sanjeev N. Mehta, Davida F. Kruger, Bruce W. Bode, Jennifer E. Layne, Bonnie Dumais, Jack R. Gallagher, Trang T. Ly

215-OR Safety and Performance of the Omnipod® Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes

6:00 – 6:15
PM

S-10 (South, Exhibition
Level) Oral Presentation

Bruce A. Buckingham, Gregory P. Forlenza, Jennifer Sherr, Alfonso Galderisi, Laya Ekhlaspour, Joon Bok Lee, Jason B. O'Connor, Bonnie Dumais, Lauren M. Huyett, Jennifer E. Layne, Trang T. Ly

**Monday,
June 10**

1357-P Real-World Glycemic Profiles and Insulin Use Patterns of 9,914 Pediatric and Adolescent Patients with Type 1 Diabetes Using the Omnipod® Insulin Management System with Cloud-Based Data Management

12:00 – 1:00
PM

Poster Hall

Jennifer E. Layne, Yibin Zheng, Jialun He, Jay Jantz, Eric Benjamin, Trang T. Ly

About the Omnipod DASH System:

Insulet's Omnipod DASH System was designed to serve as the foundation for the Company's future innovation. Designed with patient discretion and convenience in mind, the Omnipod DASH is a continuous insulin delivery system consisting of two simple components: a tubeless, waterproof*, Bluetooth® wireless technology Pod (pump) that holds up to 200 units of U-100 insulin and a modern, color touch-screen Personal Diabetes Manager (PDM) that controls the Pod. The Omnipod DASH System will have a suite of optional mobile apps for users, caregivers and HCPs to help simplify diabetes management. The Omnipod DASH System, which received FDA clearance in June 2018, is the only [DTSec](#) and [ISO 27001](#) certified insulin pump for cyber and information security and safety.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

For more information, please visit: www.insulet.com and www.myomnipod.com.

Forward-Looking Statement:

This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission in February 2019 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.

**The Pod has a waterproof IP28 rating for up to 25 feet for 60 minutes. The PDM is not waterproof.*

© 2019 Insulet Corporation. Omnipod, DASH, and Horizon are trademarks or registered trademarks of Insulet Corporation. All rights reserved.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190606005059/en/>

Source: Insulet Corporation

Investor and Corporate Communications Contact:

Deborah R. Gordon, 978-600-7717

Vice President, Investor Relations and Corporate Communications
dgordon@insulet.com

Consumer Contact:

Natalie Toomey, 978-600-7421
Marketing Manager, Global Public Relations & Field Programs
ntoomey@insulet.com